 - The subject has received cytotoxic chemotherapy including investigational cytotoxic chemotherapy within 3 weeks or nitrosoureas or mitomycin C within 6 weeks before the first dose of PD 0332991. . Patients with HER2-overexpressing tumors may receive trastuzumab up to the date of starting therapy, and may continue to receive trastuzumab while receiving PD0332991. 